As shown in Figure 7, our study demonstrated that orally administrated Api can modulate the composition of the gut microbiota, promote intestinal barrier integrity, and reduce endotoxemia caused by LPS, thus protecting mice from obesity-induced inflammation and metabolic disturbance. The gene discussed is SERPINF2; the disease is obesity disorder.